 VICTORIA , July 13, 2020 CNW - IMMUNOPRECISE ANTIBODIES LTD. the Company or IPA IPA.V IPATF TQB2.F, a leader in full-service, therapeutic antibody discovery and development, today announced the identification of additional, human lead candidate antibodies generated against SARS-CoV-2, also demonstrating potent in vitro neutralizing activity, discovered using the Companys B cell SelectTM and Single Step Cloning Hybridoma Platforms. On June 29 , IPA confirmed the identification of a series of lead candidate antibodies demonstrating potent, in vitro neutralizing activity. The Company has now added to this lead candidate pool with additional, potent neutralizing antibodies from Ligand Pharmaceuticals LGND OmniRat therapeutic human antibody platform as well as wild-type rabbits. 